{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-026192","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.263909+00:00","generated_at":"2026-05-26T22:19:32.124491+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","bullets":["Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.","Company has 180 days, until Aug 11, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","No immediate impact on listing; common stock continues to trade on Nasdaq while options to cure are explored.","If not cured by Aug 11, Ovid may seek a second 180-day period by transferring to Nasdaq Capital Market.","Failure to cure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-026192","json":"https://secwatch.observer/filing/0001193125-25-026192.json","markdown":"https://secwatch.observer/filing/0001193125-25-026192.md","text":"https://secwatch.observer/filing/0001193125-25-026192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/d385884d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:19:32.124491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3396308313fca05b9a27140187e4bf096b88184","claim":"Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001829126-26-005568","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-21T20:15:19+00:00","headline":"Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices","event_type":"other_material","sec_items":["2.02","3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005568","json":"https://secwatch.observer/filing/0001829126-26-005568.json","markdown":"https://secwatch.observer/filing/0001829126-26-005568.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"reviously disclosed, on May\n8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together\nwith the May 15 Notice, the “ Notices ”). In connection with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm"}},{"accession":"0001213900-26-058167","ticker":"SNYR","company_name":"Synergy CHC Corp.","filed_at":"2026-05-18T13:01:37+00:00","headline":"Synergy CHC receives Nasdaq delisting notice for bid price below $1.00","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058167","json":"https://secwatch.observer/filing/0001213900-26-058167.json","markdown":"https://secwatch.observer/filing/0001213900-26-058167.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/ea0291276-8k_synergy.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of\nThe Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm"}},{"accession":"0001493152-26-023889","ticker":"GCTK","company_name":"Glucotrack, Inc.","filed_at":"2026-05-15T20:45:37+00:00","headline":"Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023889","json":"https://secwatch.observer/filing/0001493152-26-023889.json","markdown":"https://secwatch.observer/filing/0001493152-26-023889.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/0001493152-26-023889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March\n31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/0001493152-26-023889-index.htm"}},{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312525026192/0001193125-25-026192-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}